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Abstract
Macrophages play a central role in host defense against mycobacterial infection and anti- TNF therapy is associated with
granuloma disorganization and reactivation of tuberculosis in humans. Here, we provide evidence for the presence of a T
cell receptor (TCR) ab based recombinatorial immune receptor in subpopulations of human and mouse monocytes and
macrophages. In vitro, we find that the macrophage-TCRab induces the release of CCL2 and modulates phagocytosis. TNF
blockade suppresses macrophage-TCRab expression. Infection of macrophages from healthy individuals with mycobacteria
triggers formation of clusters that express restricted TCR Vb repertoires. In vivo, TCRab bearing macrophages abundantly
accumulate at the inner host-pathogen contact zone of caseous granulomas from patients with lung tuberculosis. In
chimeric mouse models, deletion of the variable macrophage-TCRab or TNF is associated with structurally compromised
granulomas of pulmonary tuberculosis even in the presence of intact T cells. These results uncover a TNF-regulated
recombinatorial immune receptor in monocytes/macrophages and demonstrate its implication in granuloma formation in
tuberculosis.
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Introduction
Macrophages are key players in major chronic inflammatory
diseases including tuberculosis, atherosclerosis and rheumatoid
arthritis. Based on their myeloid origin and professional
phagocytic activity they are traditionally regarded as a pillar of
innate immunity [1]. Tuberculosis is an infectious disease that in
2008 afflicted more than nine million individuals worldwide and
claimed the lives of an estimated 1.3 million patients [2]. The
disease is caused by mycobacteria that are efficiently contained by
macrophages in highly organized immune structures, the tuber-
culous granulomas. Ample evidence indicates that the generation
and maintenance of tuberculous granulomas require TNF [3,4].
Moreover, reactivation of the disease by therapeutic TNF
blockade is associated with disruption of the granuloma architec-
ture that ultimately leads to spreading of the mycobacteria into the
surrounding tissue [5].
Within the tuberculous granuloma, cellular immunity to
mycobacteria is thought to be solely under the direction of T
cells which orchestrate the macrophage host response to the
pathogen. However, selective T cell depletion and reconstitution
experiments in murine models of tuberculosis point to the
involvement of variable host defense mechanisms in the control
of mycobacterial infection beyond T cells [6-8]. The recent
demonstration by our laboratory and others that neutrophils and
eosinophils express T cell receptors (TCR) which are generated by
V(D)J recombination has provided evidence for the existence of
variable immune receptors outside lymphocytes [9-11].
These findings and the possibility that variable immune defense
mechanisms outside T cells are implicated in the development of
the tuberculous granuloma raise the question as to whether
macrophages possess a molecular machinery for variable host
defense. Here, we report that subpopulations of monocytes and
macrophages express a recombinatorial TCRab which is TNF
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7regulated and demonstrate a role of this novel immune receptor in
the macrophage host response to mycobacteria and the formation
of the tuberculous granuloma.
Results
Subpopulations of monocytes in the circulation and
macrophages express the TCRab
To assess the possibility that monocytes, like granulocytes [9-
11], express the TCRab, we isolated human CD14
+ monocytes
from healthy donors (n=12). Expression of the TCRab in
peripheral blood monocytes was assessed in MACS-CD14
+
purified cells by immunocytochemistry using antibodies to
TCRa/TCRb and MHC-II. Utilizing this approach, we consis-
tently detected a ,5% cell fraction that displayed bright TCRab
+
expression in freshly isolated CD14
+ monocytes which showed co-
expression of MHC-II (Figure 1A). Purity of isolated CD14
+
monocytes was routinely .99.5% as determined by flow
cytometry (Figure S1A). We next characterized the TCRab
expressing monocyte subpopulation in PBMC by flow cytometry.
Consistent with immunocytochemistry, CD14
+ cells from three
normal subjects displayed positive staining for TCRb in a 3–4%
subfraction which did not exhibit staining for the T cell marker
CD3 (Figure 1B, Figure S1B). We then determined expression of
the TCRab in monocyte-derived macrophages from three healthy
donors. For this, monocytes were differentiated into naı ¨ve, IFNc
activated and IL-4 activated macrophages, respectively, on glass
slides for a period of 6 days [12] and stained for TCRab.T o
quantify the TCRab
+ populations in adherent macrophages, laser
scanning cytometry (LSC) was performed on the slides that were
immunostained with Alexa 555-labeled secondary antibodies. LSC
analysis demonstrated that a 5% subpopulation of naı ¨ve
macrophages exhibited high fluorescence indicative of TCRab
expression (Figure 1C, Figure S1C). In contrast, the fraction of
TCRab bearing macrophages was significantly higher in the IL-4
(9%) and IFNc activated macrophages (11%). Thus, activation of
macrophages induces an increase in the subpopulation of TCRab
expressing macrophages.
Immunoblot analysis confirmed the expression of the TCR a-
and b-chains in monocytes and macrophages (Figures 1D). In line
with this, immunogold electron microscopy using an antibody to
the TCR a-subunit revealed specific staining in monocyte-derived
macrophages (Figure 1E), which was detectable on the cell surface.
Next we looked for evidence of TCRab expressing macrophages in
vivo. For this, we performed double-immunostaining for the
macrophage marker CD163 and the TCRab in bronchoalveolar
lavage (BAL) fluid obtained from three individuals with normal
BAL cytology. In fact, we found that a 5–15% subpopulation of
alveolar macrophages showed positive staining for the TCRab
(Figure 1F, Figures S1D and E) demonstrating that tissue
macrophages are capable of expressing the TCR under physio-
logical conditions.
We then tested whether the TCR is also expressed in
macrophages from the mouse. Consistent with our findings in
humans, immunocytochemistry demonstrated the presence of the
TCRab in a 5–10% subfraction of spleen macrophages from
C57BL/6J mice (n=3) and RT-PCR revealed mRNA expression
of both the TCR a- and b-constant chains in splenic macrophages
(Figure 1G).
Together, these results reveal that subpopulations of peripheral
blood monocytes and in vitro activated monocyte-derived macro-
phages constitutively express the TCRab. Moreover, they
demonstrate the presence of TCRab bearing macrophages in
normal human tissue, as exemplified for the lung, and provide
evidence for TCRab expression by murine macrophages.
Monocytes/macrophages express variable TCR a- and b-
repertoires
We next investigated whether the TCRab expressed by
monocytes/macrophages represents a variable receptor. For this,
we tested whether CD14
+ monocytes and IFNc macrophages have
a rearranged TCRb locus. Using a PCR assay based on the
protocols established by van Dongen et al. [13] in combination
with sequencing of specific amplification products, evidence for
TCRb locus genomic Db1RJb (Figure 2A i) and Vb1R Jb
(Figure 2A ii) recombination was found in both the monocyte and
IFNc macrophage fractions. Length spectratyping of the antigen-
binding complementary determining region 3 (CDR3) is a well-
established method for the assessment of TCR repertoire diversity
in defined variable chains [14]. Representative Vb13a CDR3
spectratype analysis in IL-4 or IFNc primed macrophages from
healthy individuals (n=3) revealed monoclonal and oligoclonal
repertoires and varied in the same donor depending on IL-4 or
IFNc activation (Figure 2B). Sequencing of the expressed Vb13a
CDR3b clonotypes in one subject (GenBank Acc. No. JF923737-
JF923744) indeed revealed marked differences between IL-4 and
IFNc polarized macrophages (Figure 2C). Of note, quantitation of
the expressed length variants, respectively, in all three individuals
consistently demonstrated increased repertoire TCR Va and Vb
diversity in IFNc activated macrophages relative to monocytes and
IL-4 macrophages (Figure S2A).
Evidence for TCRb locus rearrangement in mature CD14
+
monocytes and our previous observation of a rearranged TCRab
in neutrophils [9] strongly suggested that TCR recombination
occurs already at an early stage of myeloid development. To test
this possibility, burst-forming unit-erythroid (BFU-E) and granu-
locyte/macrophage progenitor colonies (CFU-GM) were generat-
ed from CD34
+ hematopoietic progenitor cells of two normal
donors in two independent experiments. TCR Vb mRNA
expresssion profiling was performed on 10 randomly selected
Author Summary
Infection with mycobacteria results in a host response
which results in the formation of granulomas, highly
organized structures characterized by the presence of
macrophages, which are considered to rely solely on
invariant immune receptors. On the other hand, the
presence of variable immune receptors is required for
granuloma formation but this process is not solely
dependent on T cells. Furthermore, TNF is required for
the maintenance of the mycobacterial granuloma struc-
ture in humans. We now find evidence for subpopulations
of human and mouse macrophages that express variable
ab T cell receptors (TCRab). Engagement of the macro-
phage-TCRab triggers CCL2 release and phagocytosis of
baits directed to this receptor is enhanced. TCRab bearing
macrophages accumulate in human tuberculosis granulo-
mas and anti-TNF treatment of macrophages results in
downregulation of the TCRab, which is associated with
caspase 3 cleavage and suppression of TCRj. Anti-TNF
treatment reduces mycobacteria induced cluster formation
of TCRab positive macrophages, which is in line with
reduced granuloma formation in rag1
–/–(T cell rag1
+/+) and
TNF
–/–(T cell TNF
+/+) chimeric mice. Consequently, both
chimeras show reduced CCL2 staining after mycobacterial
infection. In summary, we have identified a recombinator-
ial immunoreceptor in monocytes/macrophages and
demonstrate its implication in mycobacterial infection.
Macrophage TCR in Tuberculosis
PLoS Pathogens | www.plospathogens.org 2 November 2011 | Volume 7 | Issue 11 | e1002375Figure 1. TCRab expression by subpopulations of human and murine monocytes/macrophages. (A) Fluorescence immunocytochemistry
demonstrating that a ,5% subpopulation of human peripheral blood CD14
+/MHC-II
+ monocytes expresses the TCRab. CD14-MACS purified
peripheral blood monocytes were isolated from a healthy donor and double-immunostained with Abs against the TCRab (red) and MHC-II (green).
Isotype controls for the anti-TCRab and anti-MHC-II antibodies are shown (right). Scale bars are indicated. Data shown are representative of n=12
donors. (B) Flow cytometry of peripheral blood mononuclear cells from a healthy individual demonstrates the presence of the TCRb on the surface of
a CD14
+ monocyte subpopulation (3.5%, red arrows). Staining for TCRb and lineage surface markers are shown. CD14
+ monocytes are in pink color,
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revealed expression of single or few rearranged Vb clonotypes in
50% (donor A) and 70% (donor B), respectively, of the CFU-GM
analyzed (Figure 2D, Figure S2B). No TCR gene expression was
observed in any of the BFU-E colonies tested (data not shown).
The majority of the CFU-GM displayed a monoclonal expression
pattern consistent with the clonogenic nature of the myeloblasts
and monoblasts in this assay. This indicates that TCRb locus
rearrangement and expression of individual-specific Vb repertoires
occurs already during the early phase of in vitro myeloid lineage
differentiation.
We next sought evidence for TCR a- and b-chain variability at
the protein level. For this, the TCRab from macrophages of
healthy donors was immunoprecipitated and subjected to
MALDI-TOF mass spectrometry. Using this proteome profiling
approach, we identified two peptides that showed partial sequence
identity with known variable TCR a-chain fragments (Ja4, Ja39)
and a total of four distinct peptides displaying partial sequence
identity with variable TCR b-chain fragments (Jb1.1, Jb1.2, Jb1.4,
Jb2.1) (Figure 2E). Three of the peptides (Ja4, Jb1.4, Jb2.1)
spanned VR J and JR C junctions indicating that they originated
from rearranged TCR a and b loci. These TCRab proteome
profiling results are consistent with the presence of multiple TCR
a- and b-chain variants in human macrophages.
In mice, TCR Vab mRNA profiling and CDR3 spectratyping
of purified peritoneal macrophages confirmed the presence of
diverse Va and Vb repertoires in wildtype macrophages. In
contrast, no evidence for TCR Vab repertoire expression was
found in macrophages from rag1
–/– mice which are incapable of
rearranging their immune receptor loci and thus lack a variable
TCRab (Figure 2F).
In summary, the combined results from TCRb VDJ rearrange-
ment analyses, Vab CDR3 mRNA expression profiling and mass
spectrometric TCRab peptide profiling indicate that the TCRab
identified in human and murine macrophages is expressed as a
variable receptor.
Macrophage-TCRab engagement induces CCL2 release
Given the presence of the TCRab ligand binding subunits in
monocytes/macrophages, we tested whether these cells also
express constituents of the TCR signaling pathway. RT-PCR
expression profiling revealed expression of all critical components
of the TCR signal transduction machinery including CD3f,
ZAP70, LAT, Fyn, and Lck, respectively, in monocytes and
macrophages from three randomly selected healthy donors
(Figure 3A). To explore whether the TCRab complex is operative
in macrophages, we next tested whether specific TCR engagement
has an impact on the secretion of effector molecules by IFNc
macrophages. Analysis of the secretory pattern of a defined panel
of cytokines, chemokines and growth factors (n=15, Table S1,
Figure S3) in response to canonical TCR stimulation with anti-
CD3 antibodies revealed enhanced secretion of the major
monocyte chemoattractant CCL2 (MCP-1) within 24 h
(Figure 3B). No detectable effect was observed for any of the
other studied macrophage effector proteins or the secretory
protein CCL5, which served as a marker for potential T cell
contamination, indicating that engagement of CD3 dependent
macrophage-TCRab signaling triggers selective secretion of CCL2
(Table S1, Figure S3). Consistent with this, anti-CD3 antibodies
induced CCL2 gene expression in IFNc macrophages (Figure 3C).
Thus, specific engagement of the TCRab in macrophages induces
gene expression and secretion of the monocyte chemoattractant
CCL2 indicating that the TCRab signal transduction pathway in
macrophages is functional.
The macrophage-TCRab modulates phagocytosis
Next, we investigated whether the TCRab interferes with the
phagocytic activity of macrophages. For this, IFNc activated
macrophages from two healthy donors were challenged with
standardized phagocytosis baits (polystyrene beads, Ø 4.5 mm) for
15 min, 1 h and 10 h, respectively. To induce physical interaction
of the baits with the macrophage-TCRab, the beads were coated
with anti-TCRa/anti-TCRb antibodies (Figure 4A). Identical
beads coupled to equal amounts of nonspecific IgG antibodies or
albumin (irrelevant protein) were used as controls. In addition,
macrophages were challenged with albumin-coated beads in the
presence of anti-TCRab antibodies that were not physically
coupled to baits. As a positive control, baits were targeted to the
known mediator of phagocytosis complement receptor 3 (CR3)
utilizing antibodies to its subunit CD11b. Using this approach, we
observed in both donors that the number of phagocytosing
macrophages was significantly increased after 1 h when baits were
directed to the TCR (1.4–3.0 fold vs. controls) (Figure 4B). This
increase was already detectable after 15 min, however, did not
reach statistical significance for all controls. A similar augmenta-
tion of phagocytosis was seen when beads were targeted to the
CR3 (1.2–4.5 fold vs. controls). In addition, we found that after
10 h baits directed to the TCR had elevated bead/cell ratios
relative to controls (1.3–1.8 fold). These findings suggest that
binding of baits to the TCRab facilitates phagocytosis. Consistent
with this, we noted that phagocytosis was unaffected when anti-
TCRab antibodies were not physically linked to beads
(Figure 4B,C). As expected, we found evidence for close proximity
of ingested baits to the TCRab (Figure 4C).
In light of the observation that the TCR facilitates phagocytosis,
we next investigated whether and to which degreee complete
CD3
+ lymphocytes in blue. (C) (Left) Laser scanning cytometry (LSC) of unstimulated (naı ¨ve) monocyte-derived macrophages stained for TCRab (red).
Nuclei are counterstained with DAPI (blue). The cytometric analysis shows a subpopulation (5%) with high fluoresence indicative of TCRab positive
naı ¨ve macrophages (top right) which is highlighted in the histogram below (arrow). (Bottom) LSC of naı ¨ve and IL-4 (10 ng/ml) or IFNc (1000 U/ml)
stimulated monocyte-derived macrophages, respectively, cultured for 6 days. The percentage of TCRab
+ cells in each macrophage population is
shown for three healthy individuals. (D) Detection of the TCR a- and b-chain in CD14
+ monocytes and IFNc or IL-4 polarized macrophages by
immunoblot. b-actin, loading control. (E) Immunogold electron microscopy demonstrating the presence of the TCR a-subunit on the cell surface of a
human IFNc stimulated macrophage (arrows). (Right) isotype control. (F) Immunocytochemical double-staining reveals the presence of the TCRab
(green) in alveolar macrophages from a 45 year old male with normal BAL cytology. Shown is a TCRab
+ alveolar macrophage (top right, arrow) next
to a TCRab
+ T cell (asterisk). The merged image (bottom right) demonstrates that the majority of the cells express the macrophage marker CD163
(red). Giemsa-staining of the BAL cytospin preparation and isotype controls are shown in the left panel. The results are representative of three
individuals. Nuclei (blue), DRAQ5. (G) Confocal immunofluorescence microscopy shows TCRab expression in murine macrophages. Spleen
macrophages pooled from three normal C57BL/6 J mice were CD11b-MACS purified and immunofluorescence double-staining was performed using
the anti-macrophage antibody F4/80 (red) and an anti-mouse TCRb antibody that recognizes a common epitope of the murine TCRab complex
(green). The outlined area is shown at a higher magnification. Nuclei (blue) are counterstained with DRAQ5. Isotype controls are shown. (Bottom) RT-
PCR demonstrating expression of the murine TCRa and TCRb constant chain genes in CD11b-MACS purified spleen macrophages (MW) from C57Bl6/J
mice. Ly6G
+ neutrophils are shown as positive control.
doi:10.1371/journal.ppat.1002375.g001
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PLoS Pathogens | www.plospathogens.org 4 November 2011 | Volume 7 | Issue 11 | e1002375Figure 2. The monocyte/macrophage TCRab is a recombinatorial receptor. (A) Detection of D R J (i) and V R DJ (ii) rearrangements in the
TCRb gene locus of human CD14
+ monocytes and IFNc macrophages. Arrows denote the presence of Db1R Jb and Vb1R Jb rearrangements which
were confirmed by sequencing. Genomic organization of the identified rearrangements is schematically drawn. Peripheral blood mononuclear cells
Macrophage TCR in Tuberculosis
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phagocytic capacity. For this, peritoneal macrophages from
recombination defective rag1
–/– mice (n=7), which lack the
TCRab (Figure 2F) were incubated with FITC-labeled Mycobac-
terium bovis Bacille-Calmette-Gue ´rin (BCG). We used mycobacteria as
baits because they represent classical macrophage pathogens and,
like CCL2, are critically implicated in macrophage-driven
granuloma formation [15]. Consistent with the findings in the
bead targeting experiments phagocytosis of M. bovis BCG was
significantly reduced in rag1
–/– macrophages compared to
recombination-competent rag1
+/+ control mice (n=7) after
6 hours of infection (Figure 4D). Together, these bait targeting
and ablation experiments strongly suggest roles of the TCRab in
the regulation of macrophage phagocytic activity.
M. bovis BCG infection induces formation of macrophage
clusters that express restricted TCR Vb repertoires in vitro
Phagocytosis of mycobacteria by macrophages with subsequent
granuloma formation are key features of host defense in
tuberculosis infection. Given this and the above results suggesting
implication of the macrophage-TCRab in phagocytosis, we next
tested whether mycobacterial challenge has an impact on TCR
expression in macrophages in vitro. We infected macrophages with
FITC-labeled M. bovis BCG and noted that within 4–6 days
macrophages routinely formed clusters (Figure 5). No clusters were
formed in the absence of mycobacteria (Figure 5B). Bacilli
frequently formed aggregates which may reflect fragmentation of
M. bovis BCG. We found evidence for co-localization of BCG and
the TCRab by immunocytochemistry (Figure 5A i) and immuno-
gold electron microscopy (Figure 5A ii), however, this phenom-
enon was rare. Quantitative analysis of BCG-infected IFNc
macrophages from two healthy donors revealed a 4-fold increase
of the percentage of TCRab
+ macrophages relative to uninfected
controls (8 vs. 32.5) (Figure 5B, Figure S4A). Consistent with this,
we found increased expression of both the TCR a and the b
constant chain genes in the macrophages that were infected with
BCG. Moreover, CDR3 spectratyping of all 25 TCR Vb chains
showed a noticeable but not significant increase in the number of
expressed Vb CDR3 length variants (12 vs 18.5) in BCG-infected
macrophages (Figure 5C). Ex situ Vb clonotype analysis of
randomly selected BCG/macrophage clusters from both donors
revealed consistent expression of highly restricted TCR Vb chain
repertoires (Figure 5D, Figure S4B). In particular, we noted a bias
toward the use of the Vb1 chain which was expressed by 10 out of
the 11 (91%) BCG/macrophage clusters analyzed. Collectively,
these results demonstrate that in vitro M. bovis BCG infection
induces formation of TCRab bearing macrophage clusters that
express highly restricted Vb repertoires.
Abundant accumulation of TCRab bearing macrophages
in human granulomas of tuberculosis
To examine whether the macrophage-TCR is implicated in
host defense against mycobacteria in vivo, we next screened for the
presence of TCRab expressing macrophages in tuberculous tissue.
Lung sections of patients with pulmonary tuberculosis (n=13,
Table S2) were immunostained for TCRaband the macrophage
markers CD68 and CD163, respectively. Ten out of 13 patients
showed abundant staining for TCRab in well-circumscribed
caseous granulomas. Typically, the innermost segment of the
epithelioid cell corona, which represents the front line of cellular
defense against mycobacteria within tuberculous granulomas,
exhibited intense TCRab
+ staining (Figure 6A i-iii). Controls
showed no staining for CD2 (Figure 6A iv,v). Quantitative analysis
of TCRabCD68 immunofluorescence double-staining revealed
that on average 87% of the macrophages expressed the TCRab in
this zone (Figures 6A vi, vii). Additional single immunofluores-
cence staining for CD68 and CD163 confirmed that the
predominant cell type in the inner host-pathogen contact zone
was macrophages (Figure 6B, Figure S5A). Consistent with this, T
cells and NK cells were typically localized in the peripheral corona
zone of caseous granulomas as assessed by CD2 immunostaining
(Figure 6B). We found no evidence for TCRab expressing
macrophages in a lymph node from an individual with reactivated
M. tuberculosis infection triggered by anti-TNF therapy (adalimu-
mab) (Figure S5B). In keeping with immunohistochemistry, ex situ
clonotype analysis revealed expression of TCR Vb mRNA
repertoires in small clusters (20–30 cells) of immunostained
CD68
+ macrophages that were laser microdissected from the
inner epithelioid cell zone (Figure 6C). Similarly as observed in
BCG infected macrophage clusters in vitro (Figure 5D), we noted
that the epithelioid zone macrophages predominantly express the
TCR Vb1 chain.
TNF blockade suppresses macrophage-TCRab expression
The cytokine TNF is essential for host defense against
mycobacteria and anti-TNF therapy may lead to disorganization
of human tuberculous granuloma resulting in reactivation of latent
tuberculosis [3,16–19]. Since activation of the TCRab in
macrophages results in CCL2 release, a key factor in granuloma
(PBMC), positive control. HepG2 cells, Ø control. (B) Expression of individual-specific TCR Vb repertoires by monocytes, IL-4 macrophages (blue) and
IFNc macrophages (red) from three healthy donors (1–3) representatively shown for Vb13a. A scaled synopsis of the three cell populations is shown at
the bottom (g). (C) TCR clonotype analysis by sequencing of the antigen-binding CDR3 loop of Vb13a representatively shown for individual 2. IL-4
(blue) and IFNc activated macrophages (red) express completely different Vb13a clonotypes. The Vb13a chain is not expressed by the monocytes of
this individual (cf. B). Colored letters represent deduced amino acid sequences of the newly identified CDR3b regions (GenBank Acc. No. JF923737-
JF923744). D) Expression of rearranged TCR Vb CDR3 clonotypes in granulocyte/macrophage progenitor colonies (CFU-GM) obtained from CD34
+
progenitors of two healthy individuals (A and B). Filled boxes indicate positive expression of at least one of the 25 known human TCR Vb chains (x-
axis) in a single colony. Colonies are identified by numbering on the y-axis. The repertoires for each of the expressed Vb chains were determined by
length variant analysis of the antigen-binding CDR3b region. The detailed Vb repertoire is representatively shown for colony CFU-GM2 (donor B). The
repertoires of additional CFU-GM colonies are summarized in Figure S2B. RT-PCR lineage marker expression profiling documents the monocytic
nature of this granulocyte/macrophage progenitor colony. CD2, CD8: T lymphoid markers; MMP25, MPO: granulocyte markers; CD14, CD68, CD163:
monocyte markers. (E) Direct mass spectrometric identification of multiple TCR Va- and Vb-chain variants in human macrophages. Protein lysates
from IFNc macrophages of a healthy donor were immunoprecipitated using an anti-TCRb antibody and the predicted 58 kD band (boxed) was
analyzed by MALDI-TOF mass spectrometry. Peaks 1–6 represent TCR Va- and Vb-specific peptide fragments whose amino acid sequence identities
with known TCR Vab-clonotypes are bolded. In three cases (2, 4 and 6), the identified peptides span VR J and JR C junctions (denoted by a gap)
indicative of genomic rearrangements in the macrophage TCRa and -b loci. (F) Peritoneal macrophages from C57Bl6/J mice (rag1
+/+) but not
recombination defective rag1
–/– mice express Va (left) and Vb repertoires (right) as evidenced by TCR V-chain mRNA expression profiling (top) and
CDR3 spectratyping of representative TCR Va- and Vb-chains (bottom). Peritoneal macrophages were pooled from three rag1
+/+ mice and an equal
number of rag1
–/– mice, respectively.
doi:10.1371/journal.ppat.1002375.g002
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impact on the expression of the macrophage-TCRab. Uninfected
or BCG infected macrophages were incubated in the presence of
the anti-TNF antibody infliximab (50 mg/ml) or an isotype control
antibody (anti-CD20, rituximab). Immunostaining revealed that
TNF blockade inhibited TCRab expression relative to controls
within 2h (Figure 7A). Consistent with this, the inhibitory effect
could be completely reversed by re-exposure of macrophages to
TNFfor 24 h indicating that macrophage-TCRabexpression
requires the presence of TNF (Figure S6A). TNF blockade also
had an inhibitory effect on TCR b-chain mRNA expression
(Figure 7B). Immunoblot revealed that TNF blockade not only
suppressed expression of the TCRab ligand binding subunit but
also that of the f-subunit (CD3) of the TCR signaling complex
(Figure 7C). The latter is essential for TCRab stabilization on the
cell surface [20] and its degradation is mediated by caspase 3 [21].
Immunoblot analysis and immunostaining showed that anti-TNF
treatment results in an increase in cleaved caspase 3 in uninfected
and BCG infected macrophages indicating that TNF blockade
induces cleaved caspase 3 (Figure 7D, Figure S6B). Because TCRf
is required for stabilizing TCRab on the cell surface these findings
identify TNF as a regulator of macrophage-TCRab expression.
Loss of macrophage-TCR is associated with granuloma
disorganization and reduced CCL2 expression in murine
tuberculosis
It is well-established that abrogation of TNF results in defective
tuberculous granulomas [7,8,22]. Given this and our finding that
BCG induces TCRab expression, we next tested whether TNF
blockade affects BCG triggered macrophage cluster formation in
vitro. We found that treatment with the anti-TNF antibody
infliximab significantly reduced the number and size of human
macrophage clusters that formed during infection with M. bovis
BCG in vitro (Figure 8A). The presence of the TCRab in mouse
macrophages offers the possibility to study the role of the TNF/
TCRab/ CCL2 regulatory axis we identified in human macro-
phages in tuberculosis in vivo. For this, we determined whether
deletion of the macrophage-TCR impacts granuloma formation
and macrophage CCL2 release in a murine model of M. tuberculosis
infection. Wildtype (wt) mice (n=5) and TCR deficient rag1
–/–
mice (n=7) that were reconstituted with wt CD3
+ T cells were
infected via aerosol with ,100 M. tuberculosis bacilli [7]. The latter
chimeric rag1
–/–(T cell wt) mice develop lung tuberculosis in the
presence of intact T cells but absence of TCR bearing
macrophages and T lymphocytes are routinely detectable in the
tuberculomas [8]. Four weeks post adoptive T cell transfer and M.
tuberculosis infection all wt mice displayed compact, well-delineated
granulomatous lesions in their lungs that were predominantly
composed of macrophages and lymphocytes (Figure 8B i,ii).
Rag1
–/–(T cell wt) chimeras lacking the TCR in their macro-
phages developed granulomatous foci containing macrophages
and lymphocytes as seen in the wildtype mice. However, these
lesions were generally diffuse (Figure 8B iii,iv) and on average 1.5
fold larger than those of control mice indicating that rag
dependent mechanisms outside the T cell system are required
for proper granuloma formation in murine tuberculosis
(Figure 8C). Importantly, immunostaining revealed abundant
CCL2 staining in the tuberculous lesions of wt mice (Figure 8B i,ii)
but CCL2 was routinely near absent in the chimeras lacking the
macrophage-TCR (Figure 8B iii,iv). Collectively, these results
demonstrate in vivo that ablation of the variable macrophage
immune receptor in murine lung tuberculosis is associated with
suppression of CCL2 and defective granulomas formation.
We finally tested the impact of TNF abrogation on CCL2
expression and tuberculoma formation in TNF deficient mice that
were reconstituted with wildtype CD3
+ T cells (TNF
–/–(T cell wt)
mice). Infection with M. tuberculosis infection in these chimeras
resulted in disorganized tuberculous granulomas in which CCL2
was consistently absent (Figure 8B v,vi). Similarly as in the
rag1
–/–(T cell wt) chimeras, the granulomatous foci in TNF
–/–(T
cell wt) mice displayed a consistent increase in size (1.7 fold vs.
Figure 3. Engagement of the macrophage TCRab induces CCL2
release. (A) Circulating human monocytes (Mono), IL-4 activated and
IFNc activated macrophages (MW), respectively, constitutively express
the genes for the TCRab chains and integral components of the TCR
signalling complex (CD3f, ZAP70, LAT, Fyn, Lck). RT-PCR profiling is
shown for three representative healthy individuals (1–3). Expression of T
cell (CD2, CD8) and monocyte/macrophage marker genes (CD14, CD68,
CD163) are demonstrated as reference. Peripheral blood monocytes
were isolated by CD14-MACS and differentiation into Th1 (IFNc) and
Th2 (IL-4) polarized MW was induced for 6 days. ZAP70, CD3f associated
protein kinase 70; LAT, linker for T cell activation; Fyn, Lck, src family
tyrosine kinases; H2O, negative control. (B) CD3 mediated TCR
activation induces selective CCL2 release from macrophages. Aliquots
of 5610
5 IFNc macrophages were incubated with soluble antibodies to
CD3, isotype control antibodies (I) or in the absence of antibodies (-) for
the indicated timepoints. CCL2 and 14 additional cytokines (Table S1)
were determined in the supernatant by multiplex cytokine assay. The
near absence of the T cell secretory protein CCL5 documents that
macrophages were virtually free of T lymphocytes (bottom). Macro-
phages were collected from two healthy donors (ind 1, ind 2). +, CD3
+ T
cells (positive control). *p,0.05. (C) TCR engagement upregulates CCL2
gene expression in macrophages as assessed by quantitative RT-PCR
(qPCR). The results shown represent the qPCR analysis of IFNc
macrophages from three healthy donors that were stimulated with
anti-CD3 antibodies for 24 h.
doi:10.1371/journal.ppat.1002375.g003
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blockade inhibits expression of the macrophage-TCR strongly
suggests that an intact TNF/TCR macrophage pathway is
required for CCL2 production in the tuberculous granuloma.
Consistent with this, we found no CCL2 expression in the
tuberculous lymphnode of a patient who received therapeutic anti-
TNF treatment (adalimumab) (Figure S7).
Discussion
In this study, we report the existence of an as yet unrecognized
recombinatorial TCRab based immune receptor in monocytes/
macrophages (macrophage-TCRab) and provide evidence for its
implication in a major infectious disease - tuberculosis. We find
that monocytes and macrophages have rearranged Vb gene loci
and consistently express diverse TCR Vab repertoires and show
that macrophage-TCRab engagement induces the release of the
monocyte chemoattractant CCL2 and demonstrate that the
expression of the novel variable immune receptor depends on
TNF. Furthermore, blockade of TNF in macrophages results in
caspase 3 cleavage, TCRf degradation and TCRab downregu-
lation.
Traditionally, variable immune receptors are thought to be
restricted to cells of lymphoid origin [1]. However, recent work
from our laboratories and others demonstrating TCRab and
TCRcd expression in neutrophils and eosinophils [9–11], antigen
receptor gene rearrangement in thymic granulocytes of mice [23],
and NK cells which display immunological memory in response to
viral infection [24] challenge this longstanding concept. These
findings, which identify lymphoid features in myeloid cells, and the
reciprocal demonstration that lymphocyte progenitors retain
myeloid potential [25] and B cells in primitive vertebrates possess
phagocytotic capabilities [26] extend the current concept of the
strict dichotomy of the vertebrate immune system into non-
specific/ myeloid and antigen-specific/ lymphoid immunity [1]
and suggest a closer kinship between both lineages than commonly
appreciated.
Figure 4. The macrophage TCRab modulates phagocytosis. (A) Schematic representation of the phagocytosis assay used for targeting of baits
to the macrophage TCRab. IFNc polarized macrophages were challenged with polystyrene bead baits (Ø 4.5 mm) coated with anti-TCRab antibodies
for 15 min, 1 h and 10 h, respectively, and uptake of beads was recorded. Beads coated with nonspecific IgG antibodies, potentially binding to the
Fcc receptor (FccR), anti-CD11b antibodies targeting the complement receptor 3 (CR3) and albumin (irrelevant protein) served as controls. In
addition, macrophages were challenged with uncoupled anti-TCRab antibodies in the presence of albumin-coated bead baits. (B) Enhanced
phagocytosis of baits targeted to the macrophage TCRab. Shown is the time course analysis of the percentage of phagocytosing cells (left) and the
bead/cell ratios (right) in IFNc macrophages that were challenged with bead baits as detailed in (A). IFNc macrophages from two healthy donors were
incubated with beads (MW:beads = 1:1, 5 mg Ab/10
7 beads) for the indicated timepoints. Quantitation of phagocytosed beads was performed by
bright field microscopy of at least 12 randomly selected fields of vision. P values refer to beads targeted to the TCR (green) or the CR3 (blue). *p,0.05,
** p,0.01, ***p,0.001; ns, not significant. (C) Representative unstained cytospin preparations (40x) of IFNc macrophages from donor 1 that were
challenged with bead baits targeted to the TCRab (top left) or albumin-coated beads in the presence of uncoupled anti- TCRab antibodies (control,
top right). DAB immunostaining of two adjacent macrophages (bottom, 100x) demonstrates the presence of the TCRab (arrows) in immediate
proximity to two ingested beads that were targeted to this immune receptor. The quantitative analysis of phagocytosed beads from this individual is
shown in (B). (D) Reduced phagocytosis of M. bovis BCG by macrophages from recombination defective rag1
–/– mice which lack the recombinatorial
TCRab. Thioglycollate-elicited peritoneal macrophages from rag1
–/– mice and rag1
+/+ wildtype control mice were infected with FITC-labeled M. bovis
BCG (MW:BCG = 1:10) and the phagocytic index was determined at the indicated timepoints by digital analysis of fluorescent images. ***p,0.001.
The data are based on the quantitative analysis of 7 pooled rag1
–/– mice and an equal number of rag1
+/+ mice. The fluorescent image (bottom)
representatively shows rag1
+/+ peritoneal macrophages after 6 h of infection with BCG. Arrows highlight ingested BCG mycobacteria. Nuclei, DAPI
(blue).
doi:10.1371/journal.ppat.1002375.g004
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macrophage-TCRab in the modulation of phagocytosis and the
macrophage response during the initial phase of mycobacterial
infection. In vivo, we find that the host/pathogen interface of
human pulmonary tuberculomas is characterized by the massive
presence of TCRab bearing macrophage-derived epithelioid cells
and deletion of the macrophage-TCR in murine tuberculosis is
associated with disorganized granuloma structure. Murine studies
have previously suggested the possibility that variable immune
receptors oustide the realm of T cells are involved in the control of
mycobacterial infection [6–8]. Our demonstration that a TNF-
dependent variable macrophage immune receptor is part of the
host defense against mycobacteria provides evidence for this
concept. In particular, our results suggest that macrophage based
antigen-specific host response mechanisms are operative in the
development of the tuberculous granuloma and thus add an all
Figure 5. Infection of macrophages with M. bovis BCG induces TCRab expression in vitro. (A) Immunofluorescence double-staining
demonstrating co-localization of BCG mycobacteria (green) and the macrophage-TCRab (red) after 6 days of infection (i). Nuclei are stained with DAPI.
Arrows highlight two double-stained points of spatial proximity (yellow fluorescence). (ii) Immunogold electron microscopy of a BCG containing
phagosome in an IFNc macrophage. The presence of a single TCRab in the immediate neighborhood of a BCG mycobacterium is shown at a higher
magnification (arrow). (B) Confocal image of a TCRab expressing macrophage cluster induced in response to in vitro infection with BCG. Uninfected
IFNc macrophages from the same donor are shown left. White arrows highlight TCRab
+ macrophages. A quantitative analysis of the percentage of
TCRab
+ cells (right) and isotype controls are shown. **p,0.01. IFNc macrophages were incubated in the presence or absence of FITC-labeled BCG for
6 days. The results represent two healthy individuals (donors A and B). Donor B see Figure S4A. (Bottom) RT-PCR demonstrating increased expression
of the TCR a- and b-chain genes in the BCG infected macrophages from both donors. GAPDH expression is shown as reference. (C) Synopsis of the
TCR Vb repertoires expressed by the BCG infected and uninfected macrophages shown in (B) assessed by CDR3 spectratyping (donor A). (Bottom)
Quantitative analysis of all Vb CDR3 length variants expressed by both donors . * p=0.07. (D) TCR Vb repertoire analysis of randomly selected BCG/
macrophage clusters from donor A reveals expression of highly restricted TCR Vb chain repertoires. BCG/macrophage clusters 1–6 were subjected to
RT-PCR and CDR3 spectratyping. The identified TCR Vb repertoires are shown for each individual cluster. Note that next to the Vb1 only few
additional Vb chains are expressed. The single peaks are indicative of monoclonality. The results are representative of two healthy individuals (donors
A and B). Donor B see Figure S4B.
doi:10.1371/journal.ppat.1002375.g005
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(Figure 9). Furthermore, since it is well established that TNF is
indispensable for the proper formation of tuberculous granulomas
[7,8,22,27], the finding that TNF blockade leads to suppression of
the macrophage-TCRab provides a novel potential mechanism
that may underly the reactivation of tuberculosis during
therapeutic anti-TNF treatment [5].
TNF dependent regulation of the macrophage-TCR implies the
involvement of the TNF receptor 1 and/or TNF receptor 2
signaling pathways in the control of expression of the novel
immune receptor. At this point, it is unclear at which level the
TNF receptor signaling cascade interferes with the macrophage-
TCR machinery. It will be challenging to identify signaling
components that connect TNF to the TCR in macrophages. Also,
it will be interesting to see if TCR activation has an impact on
TNF expression.
Given the near-ubiquitous presence of macrophages and their
involvement in acute and chronic inflammation, it is likely that the
macrophage-TCRab is implicated in further pathologies beyond
tuberculosis. Candidate diseases include chronic inflammatory
diseases such as atherosclerosis and autoimmune disorders such as
rheumatoid arthritis. Efforts are underway to further explore the
biological function of the recombinatorial macrophage receptor in
the immune response.
Materials and Methods
Isolation and culturing of monocytes/macrophages
Human monocytes/macrophages were isolated as previously
reported [28] and purified by CD14
+ Magnetic Cell Sorting
(MACS) (Miltenyi Biotec, Bergisch Gladbach, Germany) Mono-
cyte cell purity was routinely .99.5% as assessed by flow
Figure 6. Massive accumulation of TCRab
+ macrophages in the inner epithelioid cell corona of human tuberculous granulomas. (A)
Presence of the macrophage-TCRab in circumscribed caseous tuberculous granulomas. Light microscopic images i-iii reveal intense red/brown
immunostaining for the TCRab in the inner host-pathogen contact zone (bars) of the granulomas at various magnifications. (iv, v) Staining for CD2. N,
necrotic caseous core. The lung sections were obtained from a patient with pulmonary tuberculosis and are representative of 10 out of 13 randomly
selected patients (Table S2). Immunofluorescence double-staining for the TCRab (red) and the macrophage marker CD68 indicates that the TCRab
+
cells are macrophages (vi, yellow, merged). (vii) Mean percentage of CD68
+/TCRab
+ cells in the inner epithelioid cell corona of circumscribed caseous
tuberculous granulomas from 8 different patients. Percentages of double positive cells in this zone (CD68
+/TCRab
+ cells : total number of nuclei) were
determined from three sections of each patient. (B) Single immunostaining for the markers CD68 and CD163 demonstrates that macrophages
represent the vast majority of cells in the epithelioid cell corona of the caseous tuberculous granulomas (i–iii). Staining for CD2 reveals that T cells and
natural killer cells are predominantly located in the outer segment of the corona (iv). A focal accumulation of lymphocytes (L) located in the
peripheral corona zone is shown in the right box (i,v). Note positive staining for CD2 (vi). Bars in all images span the inner host-pathogen contact
zone. N, necrotic core. Isotype controls are shown in Figure S5A. ii–iv,vi: 40x. (C) Laser microdissection of a 20–30 cell cluster of CD68
+/TCRab
+
double-immunostained macrophages (encircled) from the inner host-pathogen contact zone of a caseous tuberculous granuloma. TCRab
+, red;
CD68
+, green; scale bar, 75 mm. Dissected cells are highlighted in yellow (left). Ex situ Vb CDR3 spectratype analysis of the excised cells reveals
expression of restricted TCR Vb1 repertoires.
doi:10.1371/journal.ppat.1002375.g006
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FITC (DAKO, Glastrup, Denmark), anti-CD3-PE (BD Bioscienc-
es, Franklin Lakes, USA), anti-CD2-PE (BD Biosciences), mouse
IgG1-FITC Isotype control and mouse IgG1-PE Isotype control.
CD14
+ monocytes were cultivated for 6 days in X-VIVO 10
serum-free and endotoxin-free medium (Cambrex, Verviers,
Belgium) at a concentration of 5610
5 cells/ml in the presence of
IFNc (1000 U/ml) (PeproTech, Rocky Hill, USA) or IL-4 (10 ng/
ml) (Tebu Bio, Frankfurt, Germany) to induce differentiation into
Th1 and Th2 polarized macrophages. X-VIVO 10 is an optimal
medium for cultivating human monocyte-derived macrophages
[12,28] which does not contain exogenous growth factors or
artificial stimulators of cellular proliferation. Burst-forming unit-
erythroid (BFU-E) and colony-forming units containing granulo-
cytes and macrophages (CFU-GM) were generated from human
CD34 progenitor cells as previously described [29].
Ethics statement
Infected granuloma tissue was obtained from the Department of
Pathology, Universita ¨tsmedizin Go ¨ttingen, Georg-August-Univer-
sity. Bronchial alveolar lavage fluid samples were excess material
derived from three patients in the course of their medical care.
The use of these specimens and mononuclear cells from healthy
probands was approved by the Ethics Committee of the Faculty of
Medicine Mannheim, University of Heidelberg, Germany and
Ethics Committee of the Medical University of Go ¨ttingen,
Germany. (Permit Number: 2007-254N-MA and 27/6/11). All
patient samples were stricly anonymized. In accordance with the
Declaration of Helsinki [30] no written informed consent was
provided by study participants and/or their legal guardians.
The study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. Mouse
procedures performed in this study were conducted at the
Centenary Institute, after protocol review and approval by the
University of Sydney Animal Ethics Committee (K75/3-2004/3/
3878) and at the animal facility of the Klinikum Go ¨ttingen Georg-
August-Universita ¨t (Go ¨ttingen, Germany) according to the
Deutsche Tierschutzgesetz (LAVES Niedersachsen A-008/09),
after protocol review and approval by the University of Go ¨ttingen.
Figure 7. TNF blockade inhibits expression of the macrophage-TCRab. (A) Suppression of the TCRab in uninfected and BCG infected IFNc
macrophages in response to 2h treatment with the anti-TNF antibody infliximab (50 mg/ml). An irrelevant monospecific antibody (anti-CD20) was
used as control. Macrophages were immunostained using an anti-TCRab antibody (Alexa 555-labeled, red). Representative fluorescent microscopy
images are shown. Infection with BCG mycobacteria changes the staining pattern from diffuse surface staining to a bright central spot (arrows).
Nuclei, DAPI (blue). (B) Anti-TNF treatment (infliximab) downregulates mRNA expression of the TCRb constant chain in IFNc macrophages as assessed
by qPCR. Control, uninfected macrophages. (C) Downregulation of the f-subunit of the TCR signaling complex and increased levels of cleaved
caspase 3 (D) in uninfected (controls, +TNF) and BCG infected IFNc macrophages following TNF blockade (infliximab). Controls, untreated
macrophages; +TNF, macrophages stimulated with TNF (10 ng/ml). Bar graphs (mean 6 SEM) represent quantitative analyses of qPCR or
densitometry of the immunoblots from two independent experiments. Representative immunoblots are shown. Whole cell lysates from IFNc
macrophages were immunoblotted using antibodies to TCRf, cleaved caspase 3 and b-actin, respectively. Quantitative densitometrical analyses of
the immunoblots was normalized to b-actin.
doi:10.1371/journal.ppat.1002375.g007
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and all efforts were made to minimize suffering by the attending
veterinarian.
Animal models
C57BL/6 mice and rag1 null mutant mice (rag1
–/–) were bred
and maintained at the animal facility, Klinikum Go ¨ttingen Georg-
August-Universita ¨t (Go ¨ttingen, Germany). Macrophages from the
spleen were collected and purified by CD11b-MACS for further
analyses. Thioglycollate-elicited mouse peritoneal macrophages
were collected according to standard protocols. Mice used in the
M. tuberculosis infection experiments were maintained under
specific pathogen-free conditions in the Animal Facility of the
Centenary Institute of Cancer Medicine and Cell Biology
(Newtown, Australia). Genetically modified chimeric mice were
generated by transfer of 1610
6 purified wildtype CD3
+ T cells into
TCR deficient rag1
–/– mice and TNF null mice, respectively (n=7
in each group) following whole body irradiation with 5 Gy as
previously described [7]. At the time of T cell reconstitution
wildtype, rag1
–/–(CD3 rag1
+/+) and TNF
–/–(CD3 TNF
+/+)
chimeric mice, respectively, were infected via aerosol with ,
100 M. tuberculosis bacilli (H37Rv) utilizing a Middlebrook airborne
infection apparatus. After four weeks all mice were sacrificed and
paraffin embedded lung sections were used for immunohisto-
chemical analyses.
Flow cytometry
PBMC were isolated from freshly collected whole blood or buffy
coats from healthy individuals by Ficoll density gradient
centrifugation as previously described [9]. Cells were first fixed
with 4% paraformaldehyde and then blocked with normal horse
Figure 8. Loss of the macrophage-TCR in the presence of functional T cells results in disorganized granulomas and CCL2
suppression in murine pulmonary tuberculosis. (A) TNF blockade decreases the number and size of macrophage clusters induced by BCG infection
in vitro.I F N c macrophages were infected with M. bovis BCG in the presence of the anti-TNF antibody infliximab (50 mg/ml) or an equal amount of an isotype
antibody (anti-CD20) for the indicated timepoints. Bar graphs represent total numbers of small (,100000 pixels) and large macrophage clusters (100000–
500000 pixels) that were formed. The area (number of pixels) of the macrophage clusters was determined from electronic images. The results (mean 6 SEM)
are based on the analysis of three independent donors. ** p,0.01, ***p,0.001. (B) Lung sections of wildtype (wt) mice demonstrating formation of compact,
well-circumscribed tuberculous lesions after four weeks infection with M. tuberculosis (i). A higher magnification of the boxed granuloma is shown in (ii). In
contrast, chimeric rag1
–/–(T cell wt) mice that lack the macrophage-TCR but have intact T cells develop disorganized tuberculous lesions that are consistently
larger and more diffuse than those of wildtypes (iii, iv higher magnification). All sections were immunostained for CCL2. Note intense CCL2 staining (brown) in
the tuberculous lesions of wt mice but near absence of CCL2 in the macrophage-TCR deficient rag1
–/–(T cell wt) chimeras (i–iv). Chimeric tnf
–/–(T cell wt) mice
with systemic deletion of TNF but wildtype T cells display disorganized granulomas characterized by absence of CCL2 (v, vi) similarly as observed in
macrophage-TCR deficient mice (iii, iv). All mice were infected via aerosol with , 100 M. tuberculosis bacilli at the time of adoptive T cell transfer. The lung
sections shown are representative of 5-7 mice in each experimental group. Scale bars are indicated. (C) Increased size of tuberculous granulomas in chimeric
rag1
–/–(T cell wt) and tnf
–/–(T cell wt) mice relative to wildtype controls. Shown is the mean percentage of the lung area covered by granulomatous foci
infection with M. tuberculosis. Data were calculated from scanned lung cross sections and are based on the analysis of five mice in each group.
*p ,0.05.
doi:10.1371/journal.ppat.1002375.g008
Figure 9. Proposed role of the macrophage recombinatorial
TCRab in the formation of the tuberculous granuloma and its
regulatory interactions with TNF and CCL2.
doi:10.1371/journal.ppat.1002375.g009
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was performed using the TCRbF1 antibody (clone 8A3), which
was also utilized in the immunocytochemistry and immunoblot
experiments. This framework antibody recognizes TCRab dimers.
Mouse IgG1 and IgG2b antibodies serve as isotype controls and
CD235a (purified) as a nonsense control antibody (all BD
Bioscience). Antibody binding was detected with a secondary
goat-anti-mouse FITC-labeled antibody (BD Bioscience). After
saturating with normal mouse serum (Jackson Immuno Research
Laboratories) the cells were stained with the following directly
labeled antibodies: CD45 APC-H7, CD3 PerCP-Cy5.5, CD8-PE
and CD14-APC (BD Bioscience). Analyses were performed on a
FACS Canto using the FACS Diva software (BD Bioscience).
Laser scanning cytometry (LSC)
Monocytes/macrophages were stained with mouse anti-human
TCRaF1/TCRbF1antibodies (Thermo Scientific, Waltham, USA)
in combination with Alexa Fluor 555 goat anti-mouse IgG
(Invitrogen, Carlsbad, USA) and analyzed on an iCYS laser
scanning cytometer (Compucyte, Cambridge, MA, USA). For
assessment of apoptosis, annexin V/ PI staining was used.
Contouring of cells was achieved by nuclear staining with DAPI.
Photomultiplier tube settings for voltage, offset and gain were
optimized (Figure S1C). Data were acquired and analyzed using the
iCYS cytometric acquisition and analysis software (CompuCyte).
For statistical analysis, the entire area of the microscopic slide was
scanned and for every event pictures of each channel (red, blue, and
scatter) were recorded and merged within a gallery. The count
settings selected for signal area of DAPI staining were within the
range 15–150 mm
2 in order to exclude artefacts such as debris.
Protein isolation and immunoblotting
Modified RIPA buffer was used to extract whole cell lysates. SDS-
PAGE and transfer to nitrocellulose membranes was conducted
utilising the NuPAGE protein electrophoresis systems (Invitrogen).
The primary monoclonal mouse anti-human TCRaF1/TCRbF1
antibodies (Thermo Scientific) and the polyclonoal antibodies for
cleaved caspase 3 (ASP175) or CD3 zeta (Abcam, Cambridge, UK)
were used. Mouse monoclonal antibodies to b-actin (Abcam) were
used as loading control.
Protein identification by MALDI-TOF mass spectrometry
Immunoprecipitated TCRab bands were separated by SDS-
PAGE and visualized by silver staining. The predicted 58kD single
band was excised and destained. An in-gel digestion with trypsin
was performed according to a standard protocol [31]. After o/n
incubation at 37uC, peptides were extracted with a C18 affinity
chromatography (ZipTip, Millipore) and eluted with 0.5% formic
acid in1:1(v/v) water:acetonitrile.Theeluate(1 ml)wasmixed with
saturated solution (9 ml) of a-cyano-4-hydroxycinnamic acid in 50%
CAN and 0.1%TFA, spotted onto a steel target and the droplet was
air dried prior to MS-analysis. Peptide mass fingerprinting was
performed on a MALDI-TOF-MS (Autoflex II, Bruker Daltonics)
operating in the reflector mode. The MS spectra for peaks in the
range of 1-3.5 kDa were generated by summarizing 350 laser shots
(50 laser shots at 7 different spot positions). Spectra were analyzed
using the flexanalysis software (Bruker) [31,32]. Analysis of the MS
spectra was performed utilizing the BioTools software (Bruker) in
combination with an integrated online link to the Mascot database
(www.matrixscience.com).
TCRb locus recombination assay
DNA from 10
6 monocytes, IFNc-macrophages, HepG2 (neg-
ative controls) and PBMC (positive controls) was isolated using the
Wizard Genomic DNA purification Kit (Promega). Screening for
Db R Jb and Vb R Jb rearrangements at the TCRb locus was
performed by PCR utilizing a modified non-multiplex approach
according to the protocols by van Dongen et al. [13] and
confirmed by sequencing. The customized primers used can be
requested by the authors.
TCR CDR3 length spectratyping and qPCR
RNA from all monocyte/macrophage populations was pre-
pared with TRI Reagent (Sigma) and transcribed into cDNA using
the Reverse Transcription System (Promega). RT-PCR expression
profiling of components of the TCR machinery and size
spectratyping of the antigen binding TCR Va/Vb CDR3 regions
were performed as previously reported [9]. Vab spectratypes of
the human TCR CDR3 regions were assessed on a CEQ
TM 8000
Genetic Analysis System (Beckman Coulter) using the D4-labeled
primers D4-GCAGACAGACTTGTCACTGG (TCRa) and D4-
TTGGGTGTGGGAGATCTCTGC (TCRb), respectively. To
determine the detailed CDR3 clonotypes for Vb13a, specific RT-
PCR amplification products were cloned into a pCR-TOPO
vector (TOPO TA Cloning Kit, Invitrogen) using standard
protocols. The cDNA sequences of the Vb13a CDR3 regions
were analyzed from at least 10 randomly picked clones. qPCR for
the TCRb constant chain and CCL2 was conducted using the IQ
SYBR Supermix (Biorad, Hercules, USA). B2MG and GAPDH
were used as housekeeping genes. Purity of monocyte/macro-
phage RNA was confirmed by PCR amplification of the leukocyte
lineage markers CD2, CD8, CD14, CD64, CD68, CD163,
MMP25 and MPO, respectively (exemplified in Figure 2D).
Authenticity of all relevant PCR products was confirmed by
sequencing. PCR runs were repeated at least twice. The sequences
of additional PCR primers used in this study can be requested
from the authors.
Immunocyto/-histochemistry
Before immunostaining all human and mouse tissue sections
were deparaffinized and rehydrated. For immunostaining, 5 mm
tissue sections or cells cultivated on coverslips were blocked with
5% goat serum in PBS (1% BSA), incubated with a combination of
primary antibodies at 4uC overnight, washed in PBS for 15 min,
and incubated with a combination of appropriate secondary
antibodies. The following antibodies were used: FITC-labeled
mouse anti-human CD68 (KP1, 1:50) (DakoCytomation), mouse
anti-human antibodies to TCRaF1 (clone 3A8) and TCRbF1
(clone 8A3) (1:100, Thermo Scientific), hamster anti-mouse TCRb
(clone H57-597) (1:50, BD Biosciences), mouse anti-human MHC
Class II (clone 910/D7, 1:200) (Acris Antibodies), anti-mouse F4/
80 (AbD Serotec), rabbit anti-human CD163 (Santa Cruz), anti-
mycobacterium tuberculosis-FITC (Acris, Herford, Germany),
rabbit anti-human CD2 (Thermo Scientific) and anti-cleaved
caspase 3 (ASP175) (Cell Signaling Technology, Beverly, USA).
Goat anti-mouse IgG, Alexa 488 (Invitrogen), donkey anti-rabbit
IgG, Cy3 (Dianova) (both 1:400), goat anti-hamster IgG, Alexa
488, donkey anti-rat IgG, Cy3 (Jackson ImmunoResearch) and
goat anti-mouse IgG, Alexa 555 (MoBiTec, Go ¨ttingen, Germany)
were used as secondary antibodies. Mouse IgG1 and IgG2a (BD
Biosciences), rat IgG2 (Biozol) and hamster IgG2 isotype control
antibodies (BD Biosciences) were used as negative controls. For
fluorescence imaging DRAQ5 (1:2500) (eBioscience) and Vecta-
shield Mounting Medium with DAPI (Vector Laboratories),
respectively, were used for nuclear staining. Positive staining was
either visualized by a Leica DMIRE2 microscope and the FW400
software or a Leica TCS SP-2 laser-scanning spectral confocal
microscope equipped with a 6361.32 objective (Leica Micro-
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crypton laser (568 nm) and a helium/neon laser (633 nm). Data
were acquired and analyzed using the Leica confocal software.
Two- and three-color images were acquired using a sequential
scan mode [28]. For light microscopy, samples were incubated
with the TCRa/TCRb antibodies, rabbit antibodies to CCL2
(ab7202, Abcam, Cambridge, UK) or rabbit anti-human CCL2
(ab9669, Abcam), respectively, in combination with Envision+
system-HRP anti-mouse or anti-rabbit HRP (Dako). Quantitation
of TCRab
+ cells in immunostained cytospin preparations and
tissue sections was conducted by at least two blinded assessors and
subjected to statistical analysis. For quantitation of electronic
fluorescence microscopy images the NIH image J software was
used.
Immunoelectron microscopy
IFNc stimulated macrophages were incubated in the presence
or absence of BCG for 6 h and subsequently fixed in 4 %
formaldehyde and 0.2 % glutaraldehyde (0.1 M phosphate buffer).
After washing the cells were scraped from the dish in 0.1 M
phosphate buffer containing 1% gelatin, spun down and
resuspended in 10% gelatin (0.1 M phosphate buffer) at 37uC.
The cooled gelatin pellets were cut in small blocks, infiltrated in
2.3 M sucrose in 0.1 M phosphate buffer and mounted onto
aluminum pins for ultramicrotomy before shock freezing.
Ultrathin cryosections were picked in a 1:1 mixture of 2 %
methylcellulose and 2.3 M sucrose. For immuno-labeling sections
were incubated with monoclonal antibodies specific for TCRaF1
(Thermo Scientific) and rabbit anti-mouse IgG antiserum (Rock-
land, Gilbertsville, PA, USA) followed by protein A-gold (10 nm).
Alternatively, the primary mouse antibody was detected utilizing
goat anti-mouse antibodies conjugated to gold (Aurion, Wagenin-
gen, The Netherlands). Sections were analyzed using a LEO
EM912 Omega transmission electron microscope (Zeiss, Oberko-
chen, Germany) and digital micrographs were obtained with an
on-axis 204862048-CCD camera (Proscan, Scheuring, Germany).
Laser microdissection
CD68
+/TCRab
+ cells were identified in 2 mm lung sections
from patients with pulmonary tuberculosis by immunofluorescence
microscopy (Carl Zeiss Microimaging, Go ¨ttingen, Germany).
Single double positive cells or small cell clusters were then
microdissected using a P.A.L.M. Laser Microdissection System
with laser pressure catapulting (LPC) (P.A.L.M. Microlaser
Technologies, Bernried, Germany). Total RNA from clusters of
20–30 cells was isolated using the invisorb RNA kit I (Invitek,
Berlin, Germany) and cDNA was synthesized (Superscript III
First-Strand cDNA Synthesis Kit, Invitrogen, Carlsbad, USA).
Infection with M. bovis BCG and quantitation of BCG
phagocytosis
Attenuated Mycobacterium bovis BCG (Bacillus Calmette-Gue ´rin,
BCG-medac) bacteria, strain RIVM, were re-constituted with the
supplied 0.9% NaCl solvent (BCG-Medac, Hamburg, Germany)
and used for infection of macrophages (MW:BCG = 1:10). For
quantitation of phagocytosed bacilli, BCG mycobacteria were
immunostained with a FITC-labeled antibody to M. tuberculosis
(Acris). BCG phagocytosis was quantitated from a total of 20
randomly selected fluorescence microscopy images using the NIH
image J software. The phagocytotic index (PI) was calculated as
(percentage of macrophages containing at least one bacterium) x
(mean area of bacterial staining per cell).
Assessment of BCG/ macrophage cluster areas
The areas (number of pixels) of the M. bovis BCG infected
macrophage clusters were determined from electronic images
using the image J software. From each individual 30 clusters were
analyzed.
Clonotype analysis of M. bovis BCG infected macrophages
Isolated CD14
+ cells were allowed to differentiate into
macrophages for 6 days on semisolid agarose plates (0.4% agarose
in X-VIVO 10 medium) in the presence of IFNc (1000 U/ml) and
M. bovis BCG. Single foci were collected using a 1 ml syringe
containing 100 ml PBS. cDNA was prepared using the RNeasy
MircoKit and Sensiscript RT Kit (Qiagen, Hilden, Germany) and
subjected to TCR Vb CDR3 spectratyping.
Cytokine analysis
For selective activation of the TCR, freshly obtained CD14
+
monocytes from two healthy donors were allowed to differentiate
into macrophages in the presence of IFNc. After 6 days IFNc-
polarized macrophages were washed twice with X-VIVO-10
medium (Cambrex) and co-stimulated with an endotoxin-free
mouse anti-human CD3 (1 mg/ml, Beckman Coulter) monoclonal
antibody as previously reported [9]. The culture supernatants were
collected at various timepoints and the release of a selected panel
of cytokines, chemokines and growth factors (n=15) (Table S1)
was assessed utilizing a customized Luminex-based multiplex
Procarta Cytokine Assay Kit (Multimetrix, Heidelberg, Germany).
All measurements were conducted at least in duplicate. In
addition, CCL2 (Thermo Scientific) and CCL5 (Qiagen) in the
supernatants were quantified using specific ELISAs.
Bead phagocytosis assay
For phagocytosis of baits targeted to the TCRab, IFNc-
polarized macrophages were co-incubated with polystyrene bead
baits (Ø 4.5 mm, Invitrogen) coated with anti-TCRa/anti-TCRb,
anti-CD11b (BD Biosciences), nonspecific IgG isotype control
antibodies or albumin for 15 min, 1 h and 10 h, respectively, at
37uC( M W:beads = 1:1, 5 mg protein/10
7 beads). In addition,
phagocytosis of albumin-coated beads was assessed in the presence
of uncoupled anti-TCRa/anti-TCRb antibodies. Quantitation of
phagocytosed beads was conducted by bright field microscopy of
at least 12 randomly selected fields of vision performed by two
independent observers.
Statistical analyses
Student’s t test was used to compare the significance of
differences between groups. Results were expressed as means 6
SD. p,0.05 was considered statistically significant.
Accession numbers
Human genes. TCRa-VJ: AE000660, AE000662, TCRa-
constant: X02883, TCRb: L36092, CD3f: NM_198053.2, ZAP70:
NM_001079, LAT: NM_014387, Fyn: NM_153048, Lck:
NM_001042771, CD2: NM_001767, CD8: NM_001768, CD14:
NM_000591, CD68: NM_001040059, CD163: NM_004244,
GAPDH: NM_002046.3, CCL2: NM_002982.3.
Human proteins (Swiss-Prot). TCRa: P01848, TCRb:
P01850, TNFa : P01375, CCL2 : P13500, CCL5 : P13501,
CD14: P08571, CD3: P07766, CD2: P06729, CD68 : P34810,
CD163 : Q86VB7, CR3: P11215, MHC-II : P04232, IFNc:
P01579, IL-4: P05112, b-actin : P60709.
Murine genes. TCRa: M64239, TCRb: M26053, M26057,
TCRb-V: NG_006980.
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Supporting Information
Figure S1 TCRab expression by subpopulations of
human monocytes/macrophages. (A) CD14+ cells isolated
from whole blood of healthy donors used in all experiments were
routinely .99.5 % pure before differentiation into macrophages
was induced. Shown is a representative flow cytometric analysis
using the lineage markers CD2, CD3 and CD14, respectively.
PBMC are shown as reference (left). (B) Isotype antibody (mouse
IgG2b) and irrelevant antibody (CD235a) used as negative
controls in flow cytometric analysis of TCRb expression. CD14+
monocytes are in pink color, CD3+ lymphocytes in blue. CD235a,
glycophorin A. (C) LSC gallery of naı ¨ve macrophages (CD14) and
IL-4 or IFNc activated macrophages immunostained for TCRab
(red). The iCYS image gallery depicts 25 examples of individual
events with the event of interest in the center of the image. Note
that the scanning cytometer has a broad focal plain to account for
variation in cell morphology on a flat surface. The count setting
protocol used for iCYS event collection is indicated. For
quantitation single cells were directed to a dot plot of blue (DAPI)
vs. orange (TCRab) probe MaxPixel. TCRab+ cells were
identified by setting a single gate based on orange fluorescence
in the reference coverslip on which macrophages from healthy
donors were grown. Black sections mark boundaries of analyzed
areas. Monocytes from a healthy donor were cultured on glass
coverslips for 6 days in the presence or absence of IL-4 and IFNc,
respectively, and subsequently stained with Alexa555-labeled
antibodies to TCRab. (D) Immunocytochemical double-staining
demonstrating the presence of the TCRab in normal human BAL
macrophages (patient 2, 71 y, male). The merged confocal images
show TCRab (green)/CD163 (red) double positive alveolar
macrophages. A close-up view of the outlined area is shown in
the right panel. Nuclei (blue), DRAQ5. Giemsa-staining of the
BAL cytospin preparation is shown in the left panel. KP, K.
pneumoniae. The patient showed no clinical signs of pneumonia. (E)
Immunocytochemical staining demonstrating the presence of the
TCRab (green) in normal human BAL macrophages (patient 3,
59 y, female). A close-up view of the outlined area is shown in the
right panel. The arrow points to a TCRab+ alveolar macrophage.
Nuclei (blue), DRAQ5.
(TIF)
Figure S2 (A) The monocyte/macrophage TCRab is a
recombinatorial receptor. Quantitative synopsis of the CDR3
length variants in three individuals. Global analyses of the
expressed TCR Va and Vb chain CDR3 length repertoires
(Va1-20; Vb1-25) in individuals 1- 3 reveal increased repertoire
diversity in IFNc activated macrophages relative to monocytes and
IL-4 macrophages. (B) Detailed Vb repertoires expressed by
additional CFU-GM progenitor colonies from donors A and B.
(TIF)
Figure S3 Effect of CD3 mediated TCR activation on
cytokine release from macrophages. Aliquots of 56105
IFNc macrophages were incubated with soluble antibodies to
CD3, isotype control antibodies (I) or in the absence of antibodies
(-) for the indicated timepoints as in Figure 3B. Cytokines were
determined in the supernatant by multiplex cytokine assay. The
results are summarized in Table S1. Macrophages were collected
from two healthy donors (ind 1, ind 2).
(TIF)
Figure S4 Infection of macrophages with M. bovis BCG
induces TCRab expression in vitro. (A) Confocal image of a
TCRab expressing macrophage cluster induced by infection with
BCG. Uninfected IFNc macrophages from the same donor (donor
B) are shown left. IFNc macrophages were incubated in the
presence or absence of FITC-labeled BCG for 6 days. White
arrows highlight TCRab+ macrophages. (B) TCR Vb repertoire
analysis of randomly selected BCG/macrophage clusters from
donor B reveals expression of highly restricted TCR Vb chain
repertoires. BCG/macrophage clusters 1-5 were subjected to RT-
PCR and CDR3 spectratyping. The identified TCR Vb
repertoires are shown for each individual cluster. Note that next
to the Vb1 only few additional Vb chains are expressed. The
single peaks are indicative of monoclonality.
(TIF)
Figure S5 Suppression of macrophage-TCRab expres-
sion in the tuberculous granulomas of a patient
receiving anti-TNF therapy. (A) Isotype control staining of
the macrophage markers CD68 and CD163 was performed using
the same staining conditions as in Figure 6B. Bars in both images
span the inner hostpathogen contact zone. N, necrotic caseous
core. 40x. (B) Immunofluorescence microscopy of two tuberculous
granulomas present in the lymph node of a patient with
therapeutic anti-TNF treatment (adalimumab). Paraffin sections
of the granulomas were double-stained for TCRab Alexa 555, red)
and the macrophage marker CD68 (FITC, green). Nuclei are
DAPI-stained (blue). Shown are merged images. Scale bars are
indicated. Note the consistent absence of TCR bearing macro-
phages (TCRab+/CD68+, yellow) within the granulomas. The
AFB (Acid.Fast Bacilli) test was used to confirm active infection
with acid fast mycobacteria in the patient.
(TIF)
Figure S6 TNF blockade inhibits expression of the
macrophage-TCRab. (A) Re-exposure to TNF reverses
macrophage-TCR suppression induced by TNF blockade. IFNc
activated macrophages were co-cultured in the presence of M. bovis
BCG for 24 h followed by incubation with the monospecific anti-
TNF antibody infliximab (50 mg/ml) for 2 h and 24 h, respec-
tively. Anti-TNF treatment potently inhibits macrophage-TCR
expression (red, Alexa-555 labeled) already after 2 h (left panel).
TNFstimulation 10 ng/ml) of anti-TNF treated macrophagesfor
24 h induces TCR expression (right panel). The results shown are
representative of two independent experiments. (B) Immunoflu-
orescence staining demonstrates the induction of cleaved caspase 3
(green) in uninfected and M. bovis BCG infected macrophages by
TNF blockade. Human CD14+.
(TIF)
Figure S7 Suppression of macrophage CCL2 expression
in the tuberculous granulomas of a patient receiving
anti-TNF therapy. Light microscopic immunostaining reveals
near absence of CCL2 (DAB, brown) from the lymph node of a
patient with therapeutic anti-TNF treatment (adalimumab) (right).
A lymph node from an untreated patient displaying intense CCL2
staining is shown as reference (left). Top panel, 10x; the
highlighted areas are shown at 63x magnification (bottom).
(TIF)
Table S1 Synopsis of cytokine/chemokine/growth fac-
tor release by IFNc macrophages.
(PDF)
Table S2 Histological and immunohistochemical fea-
tures of granulomas from patients with pulmonary
tuberculosis.
(PDF)
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